Shanghai Rendu Biotechnology Co. Ltd. A Total Assets
Shanghai Rendu Biotechnology Co. Ltd. A total assets. Based on the latest financial reports, Shanghai Rendu Biotechnology Co. Ltd. A (688193) holds total assets worth CN¥984.02 Million CNY (≈ $143.99 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Shanghai Rendu Biotechnology Co. Ltd. A (688193) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)
Total assets of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2025. This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See Shanghai Rendu Biotechnology Co. Ltd. A (688193) share price today for real-time trading data and today's change.
Shanghai Rendu Biotechnology Co. Ltd. A - Asset Composition Analysis
Shanghai Rendu Biotechnology Co. Ltd. A Total Assets Breakdown (December 2025)
Shanghai Rendu Biotechnology Co. Ltd. A total assets breakdown as of December 2025. Shanghai Rendu Biotechnology Co. Ltd. A's total assets of CN¥984.02 Million consist of 90.0% current assets and 10.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.8% |
| Accounts Receivable | CN¥44.79 Million | 4.5% |
| Inventory | CN¥21.24 Million | 2.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥259.91K | 0.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Shanghai Rendu Biotechnology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shanghai Rendu Biotechnology Co. Ltd. A short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Rendu Biotechnology Co. Ltd. A's current assets represent 90.0% of total assets in 2025, an increase from 58.1% in 2019.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 22.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
Shanghai Rendu Biotechnology Co. Ltd. A Competitors by Total Assets
Key competitors of Shanghai Rendu Biotechnology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$26.55 Million |
Shanghai Rendu Biotechnology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.97 | 13.47 | 9.83 |
| Quick Ratio | 14.64 | 13.10 | 9.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥830.20 Million | CN¥814.42 Million | CN¥882.42 Million |
Shanghai Rendu Biotechnology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Shanghai Rendu Biotechnology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.26 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | CN¥990.17 Million |
| Market Capitalization | $254.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Rendu Biotechnology Co. Ltd. A's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shanghai Rendu Biotechnology Co. Ltd. A's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shanghai Rendu Biotechnology Co. Ltd. A (2019–2025)
The table below shows the annual total assets of Shanghai Rendu Biotechnology Co. Ltd. A from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥990.17 Million ≈ $144.89 Million |
-0.42% |
| 2024-12-31 | CN¥994.36 Million ≈ $145.51 Million |
-5.72% |
| 2023-12-31 | CN¥1.05 Billion ≈ $154.34 Million |
-3.12% |
| 2022-12-31 | CN¥1.09 Billion ≈ $159.31 Million |
+187.56% |
| 2021-12-31 | CN¥378.61 Million ≈ $55.40 Million |
+21.82% |
| 2020-12-31 | CN¥310.79 Million ≈ $45.48 Million |
+66.14% |
| 2019-12-31 | CN¥187.07 Million ≈ $27.37 Million |
-- |
About Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of RNA molecular diagnostic technology and products. It offers products in the areas of reproductive health, bloodborne infections, respiratory infections, enterovirus infections, cancer early detection, and other areas; and AutoSAT, SuperSAT, and ultrasonic homogenizer. The company was founded in 2… Read more